Empowerment is an important factor to address everyday aspects of dealing with a chronic disease, including diabetes, according to a study that evaluated the effect of diabetes empowerment on medication adherence and self-care behaviors in adults with type 2 diabetes.
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) plans to help bring a vaccine for the Zika virus to market immediately via Emergent BioSolutions Inc., which also developed the anthrax vaccine.
Is the republican alternative ACA plan a viable trade-off? Here are some key elements of the plan to consider.
We recently asked experts to define the top challenges associated with diabetes health management, and how health plans can overcome them.
As health systems and physician groups marshal resources to launch their own plans, they must consider whether they have the necessary building blocks to successfully make the leap, how integrated a model they will pursue and whether they will build, buy or partner strategy.
Timely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.
FDA recently granted accelerated approval for obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis.
It is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.
What impact will MACRA have on your organization? We asked experts to tell us.
A new PwC Health Research Institute report notes that while strides are being made in population health, many organizations struggle to scale efforts.
FDA just granted Breakthrough Therapy Designation for the first treatment for acute graft-versus-host disease (GVHD): ruxolitinib (Jakafi, Incyte Corp.).
The first-year results of the ACA’s Risk Adjustment Program are in. Find out how it worked out and what insurers need to do next.
Boosting patient engagement is critical as the industry shifts toward value-based payments. For payers and providers, higher engagement increases the likelihood of positive outcomes at lower costs.
After initially rejecting calcifediol (Rayaldee, Opko Health) for chronic kidney disease earlier this year because of manufacturing concerns, FDA approved the drug four months ahead of its new timeline.Rayaldee extended release capsules is the first drug to receive FDA approval for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
Healthcare organizations must have sound IT project management practices in place to sensibly manage both human and financial resources. Here are nine best practices to follow.
With a high-paced career, it can be difficult to transition from work to home. We asked our editorial advisors to share their secrets.
There are more than 165,000 health- and wellness-related apps for iOS, but overall engagement remains low outside the top 10. To best benefit users, who should be responsible for health and wellness apps-employers, healthcare insurers or individual consumers? It depends.
Integrating IoT devices within healthcare systems allows professionals and individuals to have access to new health-related data used for informed, personalized healthcare applications and situations.
Tandigm Health’s first-year results highlight meaningful outcomes.
How much does diabetes cost the healthcare system and what's driving cost increases? Find out.
Here’s how remote monitoring works to improve diabetic patient care, and a look at whether payers are paying for it.
Soon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet, Janssen Biotech), the agency strengthened the existing warning about the risk of acute kidney injury with Invokana and Invokamet, as well as dapagliflozin (Farxiga and Xigduo XR, AstraZeneca).
There are four key components at the root of the changing dynamic between payers and providers. Here’s what they are, and what to do about them.
The ER Savings Initiative is designed to deliver care in a hybrid model that collaborates with health systems to eliminate the unnecessary use and costs of their ERs.
Sterling Partners’ Dan Hosler identifies the subsectors for healthcare investing that can help reduce costs and improve quality.
In 2013, its first year taking part in CMS’ Shared Savings Accountable Care Organization (ACO) Program, Rio Grande Valley Health Providers saved nearly $12 million. Here, the CEO and CMO discusses the keys to success.
HHS has announced steps aimed at limiting short-term health plans and strengthening the marketplaces. Here's how you will be affected.
Teva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch.
FDA approved the first US vaccine for cholera, Vaxchora, made by PaxVax Bermuda Ltd. in Hamilton, Bermuda. Vaxchora is the only single-dose vaccine for cholera currently licensed anywhere in the world.
Precision medicine isn’t just about genomics anymore. With the field moving forward as the next step in population health management, environmental, social and lifestyle factors that live outside the medical system are increasingly important to target treatments and engage patients. That means health plans also need innovative technology solutions to capture, store and integrate this crucial information.
